Tele: 561.316.3330
Breaking Medical Device News

Tuesday, September 21, 2021


HomeFDAFDA Approves NanoCoated Coronary Stent System Using DSG’s eClinical Systems

FDA Approves NanoCoated Coronary Stent System Using DSG’s eClinical Systems

CeloNova Biosciences, Inc., leveraging products and services provided by DSG, Inc., a leading eClinical software technology and data management global services firm, recently received US Food and Drug Administration (FDA) approval of its first-in-class COBRA PzF™ NanoCoated Coronary Stent System.

The COBRA PzF stent, which is coated with a biocompatible proprietary nanothin polymer, requires a minimum 30-day dual antiplatelet therapy regimen after intervention, according to a press release issued by the company.

“There continues to be an unmet clinical need for patients who may not be candidates for drug-eluting stents or longer term dual antiplatelet therapy,” said Donald Cutlip, M.D., principal investigator and professor of medicine at Beth Israel Deaconess Medical Center and Harvard Medical School in Boston. “Given the observed low rates of stent thrombosis and target lesion revascularization that needs to be confirmed in future studies, the COBRA PzF stent system may hold potential unique benefits for these patients.”

The stent is designed to improve coronary luminal diameter in patients with symptomatic ischemic heart disease, including diabetics, due to de novo lesions in native coronary arteries with reference vessel diameter of 2.5 mm to 4 mm and lesion length 24 mm or less, according to the release.

“DSG’s eCaseLink EDC allowed CeloNova Biosciences to manage subject enrollment and capture data efficiently in the global clinical trial of the COBRA PzF Coronary Stent. DSG handled all aspects of clinical study data management from database setup through lock. DSG’s data management team added value to their eCaseLink EDC solution by providing CeloNova Biosciences with clean, timely, and cost-effective deliverables and week-to-week metrics showing their own progress throughout the lifespan of the study,” said Mark Barakat, MD, Senior Director, Medical Affairs at CeloNova. “DSG’s clinical trial software and service experience really shined. They expertly customized databases, designed eCRFs with smart data validation and verification programming, gave us comprehensive data management plans, performed ongoing review of data and logic checks, data management, data encoding, reconciliation of serious adverse events, and database lock, submission and archiving.”

“Cardiovascular implantable electronic device trials remain an important therapeutic area of work for DSG,” said Tony Varano, CEO. “Over the past 25 years in business we have played a critical role in improving the quality of life for many NYHA class III and similar patients. The drive to help people remains at the heart of what we do every day. We thank the fantastic team at CeloNova for making DSG a part of their wonderful success story.”

DSG eClinical Systems have been used in over a hundred approvals by worldwide regulatory authorities to date.


Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

By using this website you agree to accept Medical Device News Magazine Privacy Policy